drugset / Trial / NCT03394989

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989

Phase 3 Completed 1366 enrolled Cipla Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.

Timeline

Start
2018-10-17
Primary completion
2019-12-03
Completion
2020-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications